tiprankstipranks
Trending News
More News >

HLS Therapeutics Secures Nova Scotia Reimbursement for Vascepa

Story Highlights
HLS Therapeutics Secures Nova Scotia Reimbursement for Vascepa

Don’t Miss TipRanks’ Half-Year Sale

HLS Therapeutics Inc ( (TSE:HLS) ) has issued an announcement.

HLS Therapeutics Inc. has announced a Product Listing Agreement with Nova Scotia for the public reimbursement of Vascepa, a prescription treatment for cardiovascular events, under the provincial drug plan. This agreement significantly enhances the accessibility of Vascepa in Atlantic Canada, aligning with HLS’s strategic goal to become a leading Canadian company in cardiovascular risk reduction. With this milestone, Vascepa is now accessible to over 95% of eligible patients in Canada, marking a significant expansion in its market reach.

The most recent analyst rating on (TSE:HLS) stock is a Hold with a C$3.75 price target. To see the full list of analyst forecasts on HLS Therapeutics Inc stock, see the TSE:HLS Stock Forecast page.

Spark’s Take on TSE:HLS Stock

According to Spark, TipRanks’ AI Analyst, TSE:HLS is a Neutral.

HLS Therapeutics Inc has a balanced score driven by strong technical momentum and positive corporate events, including strategic partnerships and shareholder support. However, the financial performance indicates persistent profitability challenges, and the valuation reflects current unprofitability, which weighs on the overall score.

To see Spark’s full report on TSE:HLS stock, click here.

More about HLS Therapeutics Inc

HLS Therapeutics Inc. is a pharmaceutical company established in 2015, focusing on the acquisition and commercialization of late-stage development and established branded pharmaceutical products in North America. The company targets the central nervous system and cardiovascular therapeutic areas, leveraging a management team with extensive experience in these fields.

Average Trading Volume: 12,974

Technical Sentiment Signal: Hold

Current Market Cap: C$151.5M

Find detailed analytics on HLS stock on TipRanks’ Stock Analysis page.

Disclaimer & DisclosureReport an Issue

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1